Submitted on May 31, 2019 - USP Comment Letter on “The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Insulin Biosimilar and Interchangeable Products." Docket No. FDA-2019-N-1132.
USP-comments-to-FDA-on-Insulin-Biosimilars.pdf
(259.12 KB)